| What makes a good new therapeutic l-asparaginase? A Beckett, D Gervais World Journal of Microbiology and Biotechnology 35 (10), 152, 2019 | 84 | 2019 |
| Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice DC Pryde, LH Jones, DP Gervais, MJ McCluskie, et al PLOS ONE 8 (10), e76557, 2013 | 83 | 2013 |
| Protein Deamidation in Biopharmaceutical Manufacture: Understanding, Control and Impact D Gervais Journal of Chemical Technology and Biotechnology, DOI: 10.1002/jctb.4850, 2015 | 67 | 2015 |
| Enhancing immunogenicity of a 3′ aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates MJ McCluskie, DC Pryde, DP Gervais, DR Stead, N Zhang, M Benoit, ... International immunopharmacology 16 (1), 50-56, 2013 | 62 | 2013 |
| Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates MJ McCluskie, J Thorn, DP Gervais, DR Stead, N Zhang, M Benoit, ... International immunopharmacology 29 (2), 663-671, 2015 | 43 | 2015 |
| Validation of a 30-year-old process for the manufacture of L-asparaginase from Erwinia chrysanthemi D Gervais, N Allison, A Jennings, S Jones, T Marks Bioproc Biosys Eng, 2012 | 34 | 2012 |
| Recombinant Deamidated Mutants of Erwinia chrysanthemi L-Asparaginase Have Similar or Increased Activity Compared to Wild-Type Enzyme. D Gervais, N Foote Molecular Biotechnology 56 (10), 865-877, 2014 | 33 | 2014 |
| Capillary Isoelectric Focussing of a Difficult-to-Denature Tetrameric Enzyme Using Alkylurea-Urea Mixtures D Gervais, D King Analytical Biochemistry, 10.1016/j.ab.2014.08.004, 2014 | 26 | 2014 |
| Control of process-induced asparaginyl deamidation during manufacture of Erwinia chrysanthemi L-asparaginase D Gervais, J O'Donnell, M Sung, S Smith Process Biochemistry, 2013 | 17 | 2013 |
| Characterization of the UK anthrax vaccine and human immunogenicity T Modi, D Gervais, S Smith, J Miller, S Subramaniam, K Thalassinos, ... Human Vaccines & Immunotherapeutics 17 (3), 747-758, 2021 | 13 | 2021 |
| Robust quantitation of basic-protein higher-order aggregates using size-exclusion chromatography D Gervais, A Downer, D King, P Kanda, N Foote, S Smith Journal of pharmaceutical and biomedical analysis 139, 215-220, 2017 | 12 | 2017 |
| IgE CH3 peptide vaccine AD Brown, BR Champion, C Lees, DP Gervais, LH Jones, AMK Kjerrstrom, ... US Patent 9,216,229, 2015 | 12 | 2015 |
| Structural Characterisation of Non-Deamidated Acidic Variants of Erwinia chrysanthemi L-asparaginase Using Small-Angle X-ray Scattering and Ion-Mobility Mass … D Gervais, D King, P Kanda, N Foote, L Elliott, P Brown, NO Lee, ... Pharmaceutical research 32, 3636-3648, 2015 | 11 | 2015 |
| Higher‐order structure and conformational change in biopharmaceuticals C Orphanou, D Gervais Journal of Chemical Technology and Biotechnology, 2018 | 10 | 2018 |
| Antibody purification process by precipitation DP Gervais, KA Pfeiffer US Patent App. 12/670,733, 2010 | 10 | 2010 |
| Study of radial compression high-performance liquid chromatographic columns for preparative chromatography DP Gervais, WS Laughinghouse, G Carta Journal of Chromatography A 708 (1), 41-53, 1995 | 10 | 1995 |
| Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase T Modi, D Gervais Investigational New Drugs 40 (1), 21-29, 2022 | 9 | 2022 |
| Conjugates for the prevention or treatment of nicotine addiction AD Brown, HL Davis, DP Gervais, LH Jones, JR Merson, DC Pryde, ... US Patent 8,980,276, 2015 | 7 | 2015 |
| Measurement of Subvisible Particulates in Lyophilised Erwinia chrysanthemi l-asparaginase and Relationship with Clinical Experience D Gervais, T Corn, A Downer, S Smith, A Jennings AAPS Journal, 10.1208/s12248-014-9612-9, 2014 | 6 | 2014 |
| Determination of extent of PEGylation using denaturing capillary isoelectric focussing TC Minshull, A Wood, D Roberts, C Hallam, J Lewis, A Orekoya, ... Analytical biochemistry 611, 113953, 2020 | 5 | 2020 |
Lyn JonesDana-Farber Cancer InstituteVerified email at dfci.harvard.edu
